NEUMANN is a data driven company. Up to date over 7,000 cervical samples were tested in a clinical trial the company is sponsoring. This is a tremendous opportunity to show the value of NEUMANN’s CONFIDENCE™ tests.
Over a 100 million women are screened for cervical cancer each year in the Western World and through these programs cervical cancer was reduced by 50%, but the system lacks efficiency, automation and objectivity.
Epigenetic markers on the horizon: how to triage hrHPV positive women? Presented at the 30th International Papillomavirus Conference, Sept 17-21 2015, Lisbon, Portugal.
In the clinical study the CONFIDENCE™ HPV test showed high agreement with the comparator test.
NEUMANN has a new approach: personalized risk assessment for every women. The CONFIDENCE™ Marker can establish the risk of every patient for dysplasia.
The presented 3D risk assessment map shows the probability of an underlying CIN2+ based on the patient’s age and the epigenetic test result.